Journal article
Elevated levels of apolipoprotein D predict poor outcome in patients with suspected or established coronary artery disease
Atherosclerosis, v 341, pp 27-33
01 Jan 2022
PMID: 34959206
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background and aims: Apolipoprotein D (apoD) is a lipocalin exerting neuroprotective effects. However, the relevance of apoD in respect to cardiovascular risk is largely unexplored. Therefore, this study aimed to evaluate the ability of apoD to predict future all-cause mortality, cardiovascular mortality, and cardiovascular events.
Methods: Serum apoD levels were measured in a cohort of 531 Caucasian individuals who underwent coronary angiography (356 males, 175 females; mean age 65 +/- 10 years). Fatal and non-fatal events were recorded over a median follow-up period of 5.8 years.
Results: ApoD concentrations at baseline correlated significantly with age, presence of the metabolic syndrome, body mass index, lipoprotein levels, fasting glucose, and estimated glomerular filtration rate. Kaplan-Meier curve analyses by gender-stratified quartiles of apoD revealed that the cumulative incidence rates of mortality and cardiovascular events become higher with increasing apoD levels. The adjusted hazard ratios for participants in the highest quartile of apoD compared to those in the lowest quartile were 4.00 (95% confidence interval [CI] 1.49-10.74) for overall mortality, 5.47 (95% CI 1.20-25.00) for cardiovascular mortality, and 2.52 (95% CI 1.28-5.00) for cardiovascular events.
Conclusions: High circulating levels of apoD are an indicator of poor prognosis in patients with suspected or established coronary artery disease.
Metrics
Details
- Title
- Elevated levels of apolipoprotein D predict poor outcome in patients with suspected or established coronary artery disease
- Creators
- Wijtske Annema - University Hospital of ZurichJoanna Gawinecka - University Hospital of ZurichAxel Muendlein - Vorarlberg Institute for Vascular Investigation and TreatmentChristoph H. Saely - Vorarlberg Institute for Vascular Investigation and TreatmentHeinz Drexel - Drexel University, College of MedicineArnold von Eckardstein - University Hospital of Zurich
- Publication Details
- Atherosclerosis, v 341, pp 27-33
- Publisher
- Elsevier
- Number of pages
- 7
- Grant note
- Swiss Lipid Research Award from the Arbeitsgruppe Lipide und Atherosklerose (AGLA) Dr. Karl Josef Hier and the Peter Goop Stiftung (Vaduz, Liechtenstein) 14159 / Jubilaumsfonds of the Austrian National Bank Land Vorarlberg Filling the Gap University of Zurich, Zurich, Switzerland Amgen Institute for Clinical Chemistry at the Academic Teaching Hospital Feldkirch Schweizerische Herzstiftung
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:000794865400005
- Scopus ID
- 2-s2.0-85121726198
- Other Identifier
- 991021861285304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Peripheral Vascular Disease